Focused On-demand Library for DEP domain-containing mTOR-interacting protein

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q8TB45

UPID:

DPTOR_HUMAN

Alternative names:

DEP domain-containing protein 6

Alternative UPACC:

Q8TB45; B2RCL9; B4DN97; E7EV87; Q96EQ1; Q9H0R7; Q9H894; Q9HA07

Background:

DEP domain-containing mTOR-interacting protein, also known as DEP domain-containing protein 6, plays a crucial role as a negative regulator of the mTORC1 and mTORC2 signaling pathways. By inhibiting the kinase activity of both complexes, it holds a pivotal position in controlling cellular growth, proliferation, and survival.

Therapeutic significance:

Understanding the role of DEP domain-containing mTOR-interacting protein could open doors to potential therapeutic strategies. Its critical function in regulating key signaling pathways suggests its involvement in cellular processes that, when dysregulated, can lead to disease.